Clean copy of claims for US Serial No 10/083,529

8. (new) A method of potentiating anti-angiogenic substances by the use of Poly Unsaturated Fatty Acids (PUFAs) for treating hepatocellular carcinoma, comprising:

using a combination of selected PUFA/PUFAs and a lithium salt with an anti-angiogenic substance; and,

administering said combination by one or different routes selected from a group consisting of oral, parenteral, intravenous, subcutaneous, intra-peritoneal, topical, anal, vaginal and local injection.

9. (new) The method as in claim 8 wherein said anti-angiogenic substance is selected from ANGIOSTATIN and ENDOSTATIN, and said selected PUFA is chosen from a group consisting of: linolenic acid, gamma-linolenic acid, dihomo-gamma-linolenic acid, arachidonic acid, alpha-linolenic acid, eicosapentaenoic acid, docosahexaenoic acid and cis-parinaric acid.

10. (new) The method as in claim 8 including using a lymphographic agent with said PUFAs.

11. (new) A method of selectively inhibiting endothelial cell proliferation and causing necrosis of tumor-cells by delivering a selected combination of Poly Unsaturated Fatty Acid (PUFA) in conjugation with a lithium salt, a lymphographic agent and an anti-angiogenic substance chosen from ANGIOSTATIN and ENDOSTATIN, the method including the step of administering said combination by one or different routes chosen from a group consisting of oral, parenteral, intravenous, subcutaneous, intra-peritoneal, topical, anal, vaginal and local injection.

12. (new) The method as in claim 11, wherein said PUFA comprises one or more PUFAs selected from a group consisting of linolenic acid, gamma-linolenic acid, dihomo-gamma-linolenic acid, arachidonic acid, alpha-linolenic acid, eicosapentaenoic acid, docosahexaenoic acid and cis-parinaric acid.

13. (new) A method of treating mammalian cell proliferative disorder including Hodgkin's disease, comprising the steps of:
using an emulsion of a lithium salt of a Poly Unsaturated Fatty Acid chosen from linolenic acid, gamma-linolenic acid, dihomo-gamma-linolenic acid, arachidonic acid, alpha-linolenic acid, eicosapentaenoic acid, docosahexaenoic acid and cis-parinaric acid, and,
an anti-angiogenic protein/peptide substance.

14. (new) The method as in claim 13, wherein the anti-angiogenic substance is chosen from ANGIOSTATIN and ENDOSTATIN, said method including the step of administering said emulsion and the anti-angiogenic substance orally.

15. (new) The method as in claim 13, including the step of additionally using lymphokines and anti-cancer drugs, for treating said mammalian cell proliferative disorder.

16. (new) The method as in claim 15, wherein the lymphokines include TNF (Tumor Necrosis Factor) and IFN (Interferon).

17. (new) The method as in claim 15, wherein said anticancer drugs selectively comprise Doxorubicin and Vincristine.